Direct Acting Antivirals (DAAs) – A Paradigm Change in HCV Treatment

Direct-Acting-Antiviral-Treatment-Hep-C

Chronic Hepatitis C has often been referred to as the Silent Killer as most patients with the disease does not know they have it while overtime the virus continuously causes damage to the liver leading to cirrhosis, liver failure and liver cancer. Statistics in the United States showed that liver failure due to hepatitis C is the leading cause of liver transplants.

Traditionally, Hepatitis C treatment have been treated with a 48 week course of weekly injection of interferon coupled with ribavirin. The cure rates averaged lower than 50%. Many patients complained that the commonly experienced side effects — including nausea, diarrhea, itchy skin rashes, insomnia, and severe depression — were worse than the disease itself. Patients often had to discontinue therapy as interferon injections can cause serious adverse effects including decreased red and white blood cell counts. Continue reading